English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18074/20272 (89%)
造訪人次 : 4072611      線上人數 : 841
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/32207


    標題: In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus
    作者: Tang, Hung-Jen
    Chen, Chi-Chung
    Lai, Chih-Cheng
    Zhang, Chun-Cheng
    Weng, Tzu-Chieh
    Chiu, Yu-Hsin
    Toh, Han-Siong
    Chiang, Shyh-Ren
    Yu, Wen-Liang
    Ko, Wen-Chien
    Chuang, Yin-Ching
    貢獻者: Chi Mei Med Ctr, Dept Med
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Chi Mei Med Ctr, Dept Med Res
    Chi Mei Med Ctr, Dept Intens Care Med
    Chi Mei Med Ctr, Dept Med
    Natl Cheng Kung Univ, Med Coll & Hosp, Dept Med
    關鍵字: killing effects
    tigecycline
    Vibrio vulnificus
    日期: 2018-02
    上傳時間: 2019-11-15 15:45:12 (UTC+8)
    出版者: ELSEVIER TAIWAN
    摘要: Background/purpose: The aim of this study is to investigate the role of tigecycline in Vibrio vulnificus infection. Methods: Eight randomly selected clinical V. vulnificus isolates were studied to obtain the minimal inhibitory concentrations (MICs) of minocycline, cefotaxime, and tigecycline, and the timeekill curves of tigecycline alone or in combination with other drugs. A peritonitis mouse model was used for the evaluation of the therapeutic efficacy of tigecycline alone or cefotaxime in combination with minocycline or tigecycline. Results: The MIC of minocycline, cefotaxime, and tigecycline for eight clinical V. vulnificus isolates was 0.06-0.12 mu g/mL, 0.03-0.06 mu g/mL, and 0.03-0.06 mu g/mL, respectively. In time ekilling studies, at the concentration of 1 x MIC, the inhibitory effect of tigecycline persisted for 24 hours in five of eight isolates. With 2 x MIC and trough level, the inhibitory effect was noted in all isolates for 24 hours. With the combination of minocycline plus cefotaxime and tigecycline plus cefotaxime at 1/2 x MIC, the bactericidal effect was noted in 25% and 62.5% of eight isolates and synergism in 50% and 75% of isolates. With a low (1.25 x 10(5) CFU/mL) inoculum, all infected mice survived with tigecycline alone, tigecycline plus cefotaxime, or minocycline plus cefotaxime on the 14th day. At the inoculum of 1.25 x 10(6) CFU, the survival rate was 33.3% on the 14th day in the tigecycline plus cefotaxime-treated group, but none of the mice treated by tigecycline alone or minocycline plus cefotaxime survived (33.3% vs. 0%, p = 0.01 by Fisher's exact test). Conclusion: Our in vitro combination and animal studies indicate that tigecycline could be an option for the treatment of invasive V. vulnificus infections. Copyright (C) 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
    link: http://dx.doi.org/10.1016/j.jmii.2016.04.009
    關聯: Journal of Microbiology Immunology and Infection, v.51, n.1, pp.76-81
    顯示於類別:[保健營養系(所) ] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    10.1016-j.jmii.2016.04.009.pdf377KbAdobe PDF376檢視/開啟
    index.html0KbHTML1215檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋